Состав:
Страница осмотрена фармацевтом Олейник Елизаветой Ивановной Последнее обновление 17.04.2022
Внимание! Информация на странице предназначена только для медицинских работников! Информация собрана в открытых источниках и может содержать значимые ошибки! Будьте внимательны и перепроверяйте всю информацию с этой страницы!
Топ 20 лекарств с такими-же компонентами:
Лечение гастроэзофагеальной рефлюксной болезни (ГЭРБ)
Исцеление едкого эзофагита
Эсактив показан для кратковременного лечения (от 4 до 8 недель) при заживлении и симптоматическом разрешении диагностически подтвержденного эрозивного эзофагита. Для тех пациентов, которые не зажили после 4-8 недель лечения, может быть рассмотрен дополнительный курс Esactive от 4 до 8 недель.
У детей от 1 месяца до менее 1 года эсактив показан для кратковременного лечения (до 6 недель) эрозивного эзофагита вследствие кислотоопосредованной ГЭРБ
Поддержание заживления едкого эзофагита
Эсактив показан для поддержания разрешения симптомов и заживления эрозивного эзофагита. Контролируемые исследования не продлеваются более 6 месяцев.
Симптоматическая гастроэзофагеальная рефлюксная болезнь
Эсактивный показан для кратковременного лечения (от 4 до 8 недель) изжоги и других симптомов, связанных с ГЭРБ у взрослых и детей в возрасте 1 года и старше.
Снижение риска NSAID-ассоциированной желудочной язвы
Эсактивный показан для уменьшения возникновения язв желудка, связанных с непрерывной терапией НПВП, у пациентов с риском развития язв желудка. Пациенты считаются подверженными риску из-за их возраста (≥ 60) и / или документированного анамнеза язв желудка. Контролируемые исследования не продлеваются более 6 месяцев.
Искоренение H. pylori для снижения риска рецидивов язвы двенадцатиперстной кишки
Тройная терапия (эсактивный плюс амоксициллин и кларитромицин): эсактивный, в сочетании с амоксициллином и кларитромицином, показан для лечения пациентов с Х. Пилори инфекция и язвенная болезнь двенадцатиперстной кишки (активные или исторические в течение последних 5 лет) для искоренения Х. Пилори Искоренение. Х. Пилори было показано, что он снижает риск рецидива язвы двенадцатиперстной кишки.
У пациентов, которые не проходят терапию, следует провести тестирование на восприимчивость. Если продемонстрирована устойчивость к кларитромицину или тестирование на восприимчивость невозможно, следует назначить альтернативную антимикробную терапию.
Патологические гиперсекреторные состояния, включая синдром Золлингера-Эллиса
Эсактив показан для длительного лечения патологических гиперсекреторных состояний, включая синдром Золлингера-Эллисона.
Esactive стронций используется для лечения состояний, когда в желудке слишком много кислоты. Он используется для лечения язв двенадцатиперстной кишки и желудка, эрозивного эзофагита, гастроэзофагеальной рефлюксной болезни (ГЭРБ) и синдрома Золлингера-Эллисона. Эсактив также используется с антибиотиками (например, амоксициллин, кларитромицин) для лечения язв, вызванных бактериями H. pylori. Эсактивный стронций также используется для предотвращения язв желудка и раздражения желудка у пациентов, принимающих обезболивающие и артритные препараты, называемые НПВП, такие как аспирин или ибупрофен, в течение длительных периодов времени.
Эсактивный стронций является ингибитором протонной помпы (ИПП). Это работает, уменьшая количество кислоты, которая вырабатывается желудком.
Эсактивный стронций доступен только по рецепту вашего врача.
Usual Adult Dose for Gastroesophageal Reflux Disease:
Esactive Magnesium:
-20 mg orally once a day for 4 weeks
Esactive Strontium:
-24.65 mg orally once a day for 4 to 8 weeks.
Comment:
-If symptoms do not resolve after 4 weeks, an additional 4 weeks may be considered.
GERD with Erosive Esophagitis:
Esactive Sodium:
-20 mg or 40 mg IV injection once a day, over no less than 3 minutes; or IV infusion once a day, over no less than 10 to 30 minutes
Comment: Safety and efficacy of Esactive sodium IV for Injection for more than 10 days have not been demonstrated.
Uses: Short term treatment of heartburn and symptomatic gastroesophageal reflux disease; short term treatment of GERD with erosive esophagitis, inclusively as an alternative to oral therapy, if unable to use oral route
Usual Adult Dose for Erosive Esophagitis:
Healing:
-Esactive Magnesium: 20 to 40 mg orally once a day for 4 to 8 weeks
-Esactive Strontium: 24.65 to 49.3 mg orally once a day for 4 to 8 weeks
-An additional 4 to 8 week course of therapy may be considered in patients not healed after initial treatment.
Maintenance of healing:
-Esactive Magnesium: 20 mg orally once a day
-Esactive Strontium: 24.65 mg orally once a daily
Comments:
-Esactive Sodium injection may be used as an alternative to oral therapy, if unable to use oral route.
-Maintenance of healing: Controlled studies did not extend beyond six months.
Uses: Short-term treatment in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis; to maintain symptom resolution and healing of erosive esophagitis
Usual Adult Dose for Helicobacter pylori Infection:
Esactive Magnesium:
Triple therapy:
-40 mg orally once a day for 10 days, along with amoxicillin 1000 mg and clarithromycin 500 mg orally twice a day for 10 days
Esactive Strontium:
Triple therapy:
-49.3 mg orally once a day for 10 days, along with amoxicillin 1000 mg and clarithromycin 500 mg orally twice a day for 10 days
Comments:
-Susceptibility testing should be done in patients who fail therapy.
-If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.
-Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Use: Triple therapy (Esactive plus amoxicillin and clarithromycin): Treatment of H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori
Usual Adult Dose for NSAID-Induced Gastric Ulcer:
Esactive Magnesium:
-20 mg to 40 mg orally once daily for up to 6 months
Esactive Strontium:
-24.65 mg to 49.3 mg orally once a day for up to 6 months
Comment:
-Patients older than 60 years and/or with history of gastric ulcers are considered to be at risk for developing gastric ulcers.
-Controlled studies do not extend beyond 6 months
Use: Reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers.
Usual Adult Dose for Zollinger-Ellison Syndrome:
Esactive Magnesium:
-40 mg orally twice a day
Esactive Strontium:
-49.3 mg orally twice a day
Comment: Doses up to 240 mg daily have been used.
Use: Long term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome
Usual Adult Dose for Pathological Hypersecretory Conditions:
Esactive Magnesium:
-40 mg orally twice a day
Esactive Strontium:
-49.3 mg orally twice a day
Comment: Doses up to 240 mg daily have been used.
Use: Long term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome
Usual Adult Dose for Duodenal Ulcer Prophylaxis:
Esactive Sodium:
-Initial dose: 80 mg IV infusion over 30 minutes
-Maintenance dose: 8 mg/hr IV continuous infusion for a total of 72 hours (includes initial 30 minute dose plus 71.5 hours of continuous infusion)
Comments:
-Intravenous therapy is aimed solely at the acute initial management of bleeding gastric or duodenal ulcers and does not constitute full treatment.
-Intravenous therapy should be followed by oral acid-suppressive therapy.
Use: Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy
Usual Adult Dose for Gastric Ulcer Prophylaxis:
Esactive Sodium:
-Initial dose: 80 mg IV infusion over 30 minutes
-Maintenance dose: 8 mg/hr IV continuous infusion for a total of 72 hours (includes initial 30 minute dose plus 71.5 hours of continuous infusion)
Comments:
-Intravenous therapy is aimed solely at the acute initial management of bleeding gastric or duodenal ulcers and does not constitute full treatment.
-Intravenous therapy should be followed by oral acid-suppressive therapy.
Use: Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy
Usual Pediatric Dose for Gastroesophageal Reflux Disease:
Esactive Magnesium:
Less than 1 year:
-Data not available
1 to 11 years:
-10 mg once a day for up to 8 weeks
-Comment: Doses over 1 mg/kg/day have not been studied.
12 to 17 years:
-20 mg once a day for 4 weeks
Esactive Sodium:
GERD with Erosive Esophagitis:
Less than 1 month:
-Not recommended.
1 month to less than 1 year:
-0.5 mg/kg IV infused over 10 to 30 minutes
1 to 17 years:
-Less than 55 kg: 10 mg IV infused over 10 to 30 minutes
-55 kg or more: 20 mg IV infused over 10 to 30 minutes
Esactive Strontium: Not recommended.
Uses: Short term treatment of symptomatic GERD; short term treatment of GERD with erosive esophagitis, inclusively as an alternative to oral therapy, if unable to use oral route
Usual Pediatric Dose for Erosive Esophagitis:
Esactive Magnesium:
Healing:
Less than 1 year:
-Data not available
1 to 11 years:
-Less than 20 kg: 10 mg once a day for 8 weeks
-20 kg or more: 10 mg or 20 mg once a day for 8 weeks
12 to 17 years:
-20 or 40 mg once a day for 4 to 8 weeks
Comment: Doses over 1 mg/kg/day have not been studied.
Erosive Esophagitis due to acid-mediated GERD:
Less than 1 month:
-Data not available
1 month to less than 1 year old:
-3 kg to 5 kg: 2.5 mg once a day
-Greater than 5 kg to 7.5 kg: 5 mg once a day
-Greater than 7.5 kg to 12 kg: 10 mg once a day
Duration of therapy: For up to 6 weeks
Comment: Doses over 1.33 mg/kg/day have not been studied.
1 year and older:
-Data not available
Uses: Short-term treatment in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis; short term treatment of erosive esophagitis due to acid-mediated GERD in infants
Смотрите также:
Какую самую важную информацию я должен знать об Esactive?
Эсактив быстро всасывается после перорального приема, при этом пиковые уровни в плазме происходят примерно через 1-2 часа. Это кислотный лабиль, и был разработан кишечный состав. Биодоступность Esactive увеличивается как при дозе, так и при повторном введении примерно до 68% и 89% для доз 20 мг и 40 мг соответственно. Пища задерживает и уменьшает поглощение эсактивного, но это существенно не меняет его влияние на внутригастральную кислотность. Эсактивный примерно на 97% связан с белками плазмы. Он широко метаболизируется в печени изоферментом цитохрома P450 (CYP450) CYP2C19 до метаболитов гидрокси и десметила, которые не влияют на сечение желудочной кислоты. Остальная часть метаболизируется изоферментом CYP450 CYP3A4 до эсактивного сульфона. При повторной дозировке наблюдается снижение метаболизма первого прохода и системного клиренса, вероятно, вызванного ингибированием изофермента CYP2C19. Тем не менее, нет накопления при ежедневном использовании один раз. Период полувыведения из плазмы (т½) около 1,3 часа. Почти 80% пероральной дозы выводится в виде метаболитов в моче, а остальная часть - в кале.
Use Esactive suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Esactive suspension comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Esactive suspension refilled.
- Take Esactive suspension by mouth on an empty stomach at least 1 hour before a meal.
- You will need to mix Esactive suspension in a small amount of water before taking your dose. You should use an oral syringe to measure the amount of water needed to mix your dose. Ask your pharmacist for an oral syringe. The recommended amount of water for the mixing of each dose is as follows:
- If your dose of Esactive suspension is 2.5 or 5 mg, add 1 teaspoon (5 mL) of water to a container.
- If your dose of Esactive suspension is 10, 20, or 40 mg, add 1 tablespoon (15 mL) of water to a container
- Tear open the medicine packet and add the contents of the packet to the container. Stir well. Allow the mixture to thicken for 2 to 3 minutes. Stir again. Drink the mixture within 30 minutes. If it is not used within 30 minutes, throw away this dose and mix a new dose. If any medicine remains in the glass after drinking, add more water. Stir and then drink right away.
- If the patient is taking Esactive suspension through a nasogastric (NG) tube or gastric tube, follow the instructions for use in the extra patient leaflet.
- If your doctor has instructed you to use more than 1 packet for your dose, follow the mixing instructions provided by your doctor or pharmacist.
- You may take antacids while you are using Esactive suspension if you are directed to do so by your doctor.
- Continue to take Esactive suspension even if you feel well. Do not miss any doses.
- If you miss a dose of Esactive suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Esactive suspension.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled Indications
Oral:
Esactive magnesium and Esactive strontium:
Gastroesophageal reflux disease (Rx only):
Healing of erosive esophagitis: Short-term (4 to 8 weeks) treatment of erosive esophagitis
Maintenance of healing of erosive esophagitis: Maintaining symptom resolution and healing of erosive esophagitis
Symptomatic gastroesophageal reflux disease: Short-term (4 to 8 weeks) treatment of symptomatic gastroesophageal reflux disease (GERD)
Helicobacter pylori eradication (Rx only): As part of a multidrug regimen for Helicobacter pylori eradication in patients with duodenal ulcer disease (active or history of within the past 5 years)
Risk reduction of nonsteroidal anti-inflammatory drug-associated gastric ulcer (Rx only): Prevention of gastric ulcers associated with continuous NSAID therapy in patients at risk (age ≥60 years and/or history of gastric ulcer)
Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (Rx only): Treatment (long-term) of pathological hypersecretory conditions including Zollinger-Ellison syndrome
Esactive magnesium:
Heartburn (OTC labeling): Treatment of frequent heartburn (≥2 days per week).
IV: Esactive sodium:
Gastroesophageal reflux disease (Rx only): Short-term (≤10 days) treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis in pediatric patients 1 month to 17 years of age and adults when oral therapy is not possible or appropriate
Risk reduction of ulcer rebleeding postprocedure (Rx only): Decrease the risk of rebleeding postendoscopy for acute bleeding gastric or duodenal ulcers in adults
Off Label Uses
Barrett esophagus
Data from a meta-analysis of observational studies evaluating acid suppressive therapy and the risk of esophageal adenocarcinoma or high-grade dysplasia in patients with Barrett esophagus showed that proton pump inhibitors were associated with a reduction in the risk of esophageal adenocarcinoma and high-grade dysplasia associated with Barrett esophagus; a longer duration of PPI use was associated with a greater protective effect.
See also:
What other drugs will affect Esactive?
Esactive is extensively metabolized in the liver by CYP2C19 and CYP3A4.
In vitro and in vivo studies have shown that Esactive is not likely to inhibit CYPs 1A2, 2A6, 2C9, 206, 2E1 and 3A4. No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected. Drug interaction studies have shown that Esactive does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin. Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and Esactive therapy. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
Esactive may potentially interfere with CYP2C19, the major Esactive metabolizing enzyme. Coadministration of Esactive 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam. Increased plasma levels of diazepam were observed 12 hours after dosing and onwards. However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.
Concomitant administration of Esactive and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the Esactive exposure. Dose adjustment of Esactive is not normally required for the recommended doses. However, in patients who may require higher doses, dose adjustment may be considered.
Esactive acts as an inhibitor of CYP2C19. Esactive given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased Cmax and AUC of cilostazol by 18% and 26% respectively. Cmax and AUC of one of its active metabolites, 3,4-dihydro-cilostazol, which has 4-7 times the activity of cilostazol, were increased by 29% and 69% respectively. Co-administration of cilostazol with Esactive is expected to increase concentrations of cilostazol and its above mentioned active metabolite. Therefore a dose reduction of cilostazol from 100 mg b.i.d. to 50 mg b.i.d. should be considered.
Co-administration of' oral contraceptives, diazepam, phenytoin, or quinidine did not seen to change the pharmacokinetic profile of Esactive.
Antiretroviral Agents: Concomitant use of atazanavir and nelfinavir with proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.
Esactive has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during Esactive treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and Esactive (40 mg qd). AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and Esactive (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%. Concomitant administration with Esactive and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increases in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with Esactive 40 mg qd coadministered days 11 to 15. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with Esactive.
Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with Esactive.
Studies evaluating concomitant administration of Esactive and either naproxen (non-selective NSAID) or rofecoxib (COX-2 selective NSAID) did not identify any clinically relevant changes in the pharmacokinetic profiles of Esactive or these NSAIDs.
Esactive inhibits gastric acid secretion. Therefore, Esactive may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
See also:
What are the possible side effects of Esactive?
Clinical Trials Experience with
Intravenous Esactive
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The safety of intravenous Esactive is based on results from clinical trials conducted in four different populations including patients having symptomatic GERD with or without a history of erosive esophagitis (n=199), patients with erosive esophagitis (n=160), healthy subjects (n=204) and patients with bleeding gastric or duodenal ulcers (n=375).
Symptomatic GERD and Erosive Esophagitis Trials
The data described below reflect exposure to Esactive I.V. for Injection in 359 patients. Esactive I.V. for Injection was studied only in actively-controlled trials. The population was 18 to 77 years of age; 45% Male, 52% Caucasian, 17% Black, 3% Asian, 28% Other, and had either erosive reflux esophagitis (44%) or GERD (56%). Most patients received doses of either 20 or 40 mg either as an infusion or an injection. Adverse reactions occurring in ≥1% of patients treated with intravenous Esactive (n=359) in clinical trials are listed below:
Intravenous treatment with Esactive 20 and 40 mg-administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of Esactive.
Pediatric
A randomized, open-label, multi-national study to evaluate the pharmacokinetics of repeated intravenous doses of once daily Esactive in pediatric patients 1 month to 17 years old, inclusive was performed. The safety results are consistent with the known safety profile of Esactive and no unexpected safety signals were identified [seeClinical Pharmacology (12.3)].
Risk Reduction of Rebleeding of Gastric or Duodenal Ulcers in Adults
The data described below reflect exposure to Esactive I.V. for Injection in 375 patients. Esactive I.V. for Injection was studied in a placebo-controlled trial. Patients were randomized to receive Esactive I.V. for Injection (n=375) or placebo (n=389). The population was 18 to 98 years old; 68% Male, 87% Caucasian, 1% Black, 7% Asian, 4% other, who presented with endoscopically confirmed gastric or duodenal ulcer bleeding. Following endoscopic hemostasis, patients received either 80 mg Esactive as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for a total treatment duration of 72 hours. After the initial 72-hour period, all patients received oral proton pump inhibitor (PPI) for 27 days.
With the exception of injection site reactions described above, intravenous treatment with Esactive administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of Esactive.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Esactive. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Postmarketing Reports - There have been spontaneous reports of adverse events with postmarketing use of Esactive. These reports occurred rarely and are listed below by body system:
Blood And Lymphatic System Disorders: agranulocytosis, pancytopenia; Eye Disorders: blurred vision; Gastrointestinal Disorders: pancreatitis; stomatitis; microscopic colitis; Hepatobiliary Disorders: hepatic failure, hepatitis with or without jaundice; Immune System Disorders: anaphylactic reaction/shock; Infections and Infestations: GI candidiasis; Metabolism and nutritional disorders: hypomagnesemia with or without hypocalcemia and/or hypokalemia; Musculoskeletal And Connective Tissue Disorders: muscular weakness, myalgia, bone fracture; Nervous System Disorders: hepatic encephalopathy, taste disturbance; Psychiatric Disorders: aggression, agitation, depression, hallucination; Renal and Urinary Disorders: interstitial nephritis; Reproductive System and Breast Disorders: gynecomastia; Respiratory, Thoracic and Mediastinal Disorders: bronchospasm; Skin and Subcutaneous Tissue Disorders: alopecia, erythema multiforme, hyperhidrosis, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN, some fatal).
Other adverse events not observed with Esactive, but occurring with omeprazole can be found in the omeprazole package insert, ADVERSE REACTIONS section.
Каждая таблетка содержит 20 или 40 мг эсактивного (в виде тригидрата магния).
Каждая таблетка содержит эсомепразол в виде гранул с энтеросолюбильным покрытием (MUPS).
Esactive MUPS является ингибитором протонной помпы. Активным ингредиентом Esactive MUPS является тригидрат магния Esactive, замещенный бензимидазол. Эсактивный является S-изомером омепразола. Это оптически стабильно in vivoс незначительным преобразованием в R-изомер. Химическое название ди- (S) -5-метокси-2 - [[4-метокси-3,5-диметил-2-пиридинил) метил] сульфинил] -1H- тригидрат соли магния бензимидазола.
Его молекулярная формула C34H36N6O6S2Mg · 3H2O и имеет молекулярную массу 767,2 (тригидрат).
Вспомогательные вещества / Неактивные ингредиенты: Глицерин моностеарат 40-55, гипролоза, гипромеллоза, оксид железа (Е 172) ,(Таблетка 20 мг, красновато-коричневый CI 77491, желтый, CI 77492) ,(Таблетка 40 мг, красновато-коричневый CI 77491) стеарат магния, этилакрилатный сополимер метакриловой кислоты (1: 1) дисперсия 30 процентов, целлюлоза микрокристаллическая, синтетический парафин, макроголы, полисорбат 80, кросповидон, стеарилфумарат натрия, сахарные сферы (сахароза и кукурузный крахмал) тальк, диоксид титана (Е 171) триэтилцитрат.
Эсактив 20 мг : Сахароза 28 мг.
Эсактив 40 мг : Сахароза 30 мг.
Однако мы предоставим данные по каждому действующему веществу